Portal de Periódicos da CAPES

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

2004; Springer Nature; Volume: 23; Issue: 31 Linguagem: Inglês

10.1038/sj.onc.1207691

1476-5594

Sylvie Berthou, Daniel M. Aebersold, Laura S. Schmidt, Deborah Stroka, Christine Heigl, Bruno Streit, Denise Stalder, Guenther Gruber, Congxin Liang, Anthony R. Howlett, Daniel Candinas, Richard Greiner, Kenneth E. Lipson, Yitzhak Zimmer,

PI3K/AKT/mTOR signaling in cancer

Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects the kinase activity and subsequent signaling of various mutant forms of Met. Two Met variants tested, M1268T and H1112Y, were potently inhibited by 2 μ M SU11274, while two other variants, L1213V and Y1248H, remained resistant under similar experimental conditions. Inhibition of the kinase altered cell proliferation, morphology and motility, while cells containing resistant mutants appeared unaffected by the compound. The basis for the sensitivity or resistance to SU11274 is discussed in terms of the position of the mutations predicted from a homology model.